Skip to main content

Advertisement

SpringerLink
Log in

Polypharmacy and Rational Prescribing: Changing the Culture of Medicine One Patient at a Time

  • Geriatric Rehabilitation (P Kortebein, Section Editor)
  • Published:
Current Physical Medicine and Rehabilitation Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Polypharmacy and the associated concept of potentially inappropriate prescribing (PIP) have well-documented deleterious effects on older adults and other vulnerable groups commonly treated by physiatrists. Addressing the issues of polypharmacy and PIP presents an opportunity to improve health and rehabilitation outcomes. In this article, we review medications commonly initiated and managed by physiatrists such as anticoagulants, antidepressants, neuro-stimulants, and pain medications based on current evidence. We also offer strategies to minimize polypharmacy and PIP by exploring alternative and behavioral approaches to common clinical issues in rehabilitation according to the most recent guidelines.

Recent Findings

Polypharmacy is associated with a host of undesirable and potentially preventable outcomes including falls, hip fractures, delirium, incontinence, and cognitive impairments. As the number of medications increase, so does the risk of untoward effects.

Summary

Physiatrists are well positioned to have a positive impact on rational prescribing and polypharmacy given our emphasis on function, familiarity with non-medication treatment modalities, and an embrace of a biopsychosocial orientation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Geller AI, Nopkhun W, Dows-Martinez MN, Strasser DC. Polypharmacy and the role of physical medicine and rehabilitation. PM R. 2012;4:198–219. https://doi.org/10.1016/j.pmrj.2012.02.012. This review article is the most comprehensive review of polypharmacy specific to PM&R. It presents the broad context of the issue, detailed summaries of medications commonly used in PM&R, and practical strategies to manage polypharmacy and PIP specifically in rehabilitation settings.

    Article  PubMed  Google Scholar 

  2. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry. 2011;19:211–21. https://doi.org/10.1097/JGP.0b013e3181f1803d.

    Article  PubMed  Google Scholar 

  3. Taylor WD. Depression in the elderly. N Engl J Med. 2014;371(13):1228–36. https://doi.org/10.1056/NEJMcp1402180.

    Article  CAS  PubMed  Google Scholar 

  4. •• Choosing Wisely Workgroup AGS. AGS Choosing Wisely Workgroup. American Geriatrics Society identifies another five things that healthcare providers and patients should question. J Am Geriatr Soc. 2014;62(5):950–60. https://doi.org/10.1111/jgs.12770. The Choosing Wisely Initiative is a program of the American Board of Internal Medicine and the American Geriatrics Society which identifies 10 key areas where providers’ actions can improve the care of older adults. Seven of the ten areas involve medication prescribing practices (over and / or inappropriate medications). These recommendations highlight the broad consensus on the importance of carefully selecting medications for older patients.

    Article  Google Scholar 

  5. Chapman IM. Weight loss in older persons. Med Clin North Am. 2011;95:579–93. https://doi.org/10.1016/j.mcna.2011.02.004.

    Article  PubMed  Google Scholar 

  6. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097–105. https://doi.org/10.1056/NEJM199910073411501.

    Article  CAS  PubMed  Google Scholar 

  7. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340(24):1888–99. https://doi.org/10.1056/NEJM199906173402407.

    Article  CAS  PubMed  Google Scholar 

  8. Brewster GS, Riegel B, Gehrman PR. Insomnia in the older adult. Sleep Med Clin. 2018;13(1):13–9. https://doi.org/10.1016/j.jsmc.2017.09.002.

    Article  PubMed  Google Scholar 

  9. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165:125–33. https://doi.org/10.7326/M15-2175.

    Article  PubMed  Google Scholar 

  10. •• American Geriatrics Society 2019 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;63(11):2227–46. https://doi.org/10.1111/jgs.13702. The Beers Criteria compiled by the American Geriatrics Society (AGS) represents the most comprehensive statement and guidelines on potentially inappropriate medication use in older adults with a particular relevance to the frail older individual. The Criteria represents a consensus of experts associated with the AGS. An updated version is currently under review with an anticipated publication in 2019 .

    Article  Google Scholar 

  11. •• O'Mahony D, O'Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8. https://doi.org/10.1093/ageing/afu145. The STOPP / START criteria is likely the most common and established method for managing inappropriate prescribing in the U.S. It’s utility and overall characteristics have been confirmed by peer review research and expert guidelines.

    Article  PubMed  Google Scholar 

  12. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337–44. https://doi.org/10.1001/jama.287.3.337.

    Article  PubMed  Google Scholar 

  13. Lombardi TP, Kennicutt JD. Promotion of a safe medication environment: focus on the elderly and residents of long-term care facilities. Medscape Pharmacists. 2001;2(1):23–8.

    Google Scholar 

  14. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https://doi.org/10.1186/s12877-017-0621-2.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Alagiakrishnan K, Wiens C. An approach to drug induced delirium in the elderly. Postgrad Med J. 2004;80(945):388–93. https://doi.org/10.1136/pgmj.2003.017236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107(2):169–73. https://doi.org/10.7326/0003-4819-107-2-169.

    Article  CAS  PubMed  Google Scholar 

  17. Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15–28. https://doi.org/10.2165/00002512-199915010-00002.

    Article  CAS  PubMed  Google Scholar 

  18. Huffman GB. Evaluating and treating unintentional weight loss in the elderly. Am Fam Physician. 2002;65(4):640–50.

    PubMed  Google Scholar 

  19. Jyrkka J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20(5):514–22. https://doi.org/10.1002/pds.2116.

    Article  PubMed  Google Scholar 

  20. Gnjidic D, Hilmer SN, Blyth FM, Nagananthan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–95. https://doi.org/10.1016/j.jclinepi.2012.02.018.

    Article  PubMed  Google Scholar 

  21. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore). 2010;89(5):295–9. https://doi.org/10.1097/MD.0b013e3181f15efc.

    Article  Google Scholar 

  22. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc. 1999;47(1):40–50. https://doi.org/10.1111/j.1532-5415.1999.

    Article  CAS  PubMed  Google Scholar 

  23. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 1999;47(1):30–9. https://doi.org/10.1111/j.1532-5415.1999.

    Article  CAS  PubMed  Google Scholar 

  24. Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998;339(13):875–82.

    Article  CAS  Google Scholar 

  25. Talasz H, Lechleitner M. Polypharmacy and incontinence. Z Gerontol Geriatr. 2012;45(6):464–7. https://doi.org/10.1007/s00391-012-0358-7.

    Article  CAS  PubMed  Google Scholar 

  26. Akazawa M, Imai H, Igarashi A, Tsutani K. Potentially inappropriate medication use in elderly Japanese patients. Am J Geriatr Pharmacother. 2010;8(2):146–60.

    Article  Google Scholar 

  27. Lopez-Sendon JL, Mena MA, de Yebenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging. 2012;29(2):105–18.

    Article  CAS  Google Scholar 

  28. Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med. 1997;157(18):2089–96. https://doi.org/10.1001/archinte.1997.00440390083011.

    Article  CAS  PubMed  Google Scholar 

  29. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group. JAMA. 1997;277(4):307–11. https://doi.org/10.1001/jama.1997.03540280045032.

    Article  CAS  PubMed  Google Scholar 

  30. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med. 1995;155(18):1949–56. https://doi.org/10.1001/archinte.1995.00430180043006.

    Article  CAS  PubMed  Google Scholar 

  31. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–5. https://doi.org/10.1001/jama.279.15.1200.

    Article  CAS  PubMed  Google Scholar 

  32. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571–84. https://doi.org/10.2174/092986710790416326.

    Article  CAS  PubMed  Google Scholar 

  33. Shi S, Morike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol. 2008;64(2):183–99. https://doi.org/10.1007/s00228-007-0422-1.

    Article  PubMed  Google Scholar 

  34. Palmer AK, Kirkland JL. Aging and adipose tissue: potential interventions for diabetes and regenerative medicine. Exp Gerontol. 2016;86:97–105. https://doi.org/10.1016/j.exger.2016.02.013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Jonker MJ, Melis JP, Kuiper RV, van der Hoeven TV, Wackers PFK, Robinson J, et al. Life spanning murine gene expression profiles in relation to chronological and pathological aging in multiple organs. Aging Cell. 2013;12(5):901–9. https://doi.org/10.1111/acel.12118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19–28. https://doi.org/10.1053/j.ackd.2015.08.004.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Alfaras I, Di Germanio C, Bernier M, Csiszar A, Ungvari Z, Lakatta EG. Pharmacological strategies to retard cardiovascular aging. Circ Res. 2016;118(10):1626–42. https://doi.org/10.1161/CIRCRESAHA.116.307475.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. https://doi.org/10.1001/jamainternmed.2014.7663.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Byrne CJ, Walsh C, Cahir C, Ryan C, Williams DJ, Bennett K. Anticholinergic and sedative drug burden in community-dwelling older people: a national database study. BMJ Open. 2018;8:e022500. https://doi.org/10.1136/bmjopen-2018-022500.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Gorup E, Rifel J, Petekšter M. Anticholinergic burden and most common anticholinergic-acting medicines in older general practice patients. Zdr Varst. 2018;57(3):140–7. https://doi.org/10.2478/sjph-2018-0018.

    Article  PubMed  PubMed Central  Google Scholar 

  41. • Naples JG, Marcum ZA, Perera S, Gray SL, Newman AB, Simonsick EM, et al. Concordance between anticholinergic burden scales. J Am Geriatr Soc. 2015;63(10):2120–4. https://doi.org/10.1111/jgs.13647. Anticholinergic effects of medications are a powerful cause of medication side-effects and the untoward impact of polypharmacy. This review article presents the state of the art in measuring anticholinergic burden. Anticholinergic burden measurements offer clinicians and researchers useful tools to gauge the impact of medications and to compare strategies to evaluate and improve prescribing practices.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Lattanzio F, Onder G, La Fauci MM, Volpato S, Cherubini A, Fabbietti P, et al. Anticholinergic burden is associated with increased mortality in older patients with dependency discharged from hospital. J Am Med Dir Assoc. 2018;19(11):942–7. https://doi.org/10.1016/j.jamda.2018.06.012.

    Article  PubMed  Google Scholar 

  43. Jamsen KM, Gnjidic D, Hilmer SN, Ilomäki J, Le Couteur DG, Blyth F, et al. Drug burden index and change in cognition over time in community-dwelling older men: the CHAMP study. Ann Med. 2017;49:157–64. https://doi.org/10.1080/07853890.2016.1252053.

    Article  PubMed  Google Scholar 

  44. Fox C, Smith T, Maidment I, Chan W, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604–15. https://doi.org/10.1093/ageing/afu096.

    Article  PubMed  Google Scholar 

  45. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–7. https://doi.org/10.1001/archinte.167.8.781.

    Article  PubMed  Google Scholar 

  46. Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington (DC): Institute of Medicine (US) Committee on Quality of Health Care in America. National Academy Press (US); 2000. https://doi.org/10.17226/9728.

    Book  Google Scholar 

  47. Center for Drug Evaluation and Research. “Drug safety and availability - FDA Drug safety communication: FDA study of medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with pradaxa (Dabigatran) compared to warfarin.” U S Food and Drug Administration Home Page, Center for Drug Evaluation and Research, 2 Nov. 2012, www.fda.gov/Drugs/DrugSafety/ucm396470.htm#tabs-7.

  48. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. https://doi.org/10.1056/NEJMoa1009638.

    Article  CAS  PubMed  Google Scholar 

  49. Hohnloser SH, Shestakovska O, Eikelboom J, Franzosi MG, Tan RS, Zhu J, et al. The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. Eur Heart J. 2013;34(35):2752–9. https://doi.org/10.1093/eurheartj/eht292.

    Article  CAS  PubMed  Google Scholar 

  50. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039.

    Article  CAS  PubMed  Google Scholar 

  51. Van Damme A, Declercq T, Lemey L, Tandt H, Petrovic M. Late-life depression: issues for the general practitioner. Int J Gen Med. 2018;11:113–20. https://doi.org/10.2147/IJGM.S154876.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Kok RM, Reynolds CF. Management of depression in older adults: a review. JAMA. 2017;317(20):2114–22. https://doi.org/10.1001/jama.2017.5706.

    Article  CAS  PubMed  Google Scholar 

  53. • Torvinen-Kiiskinen S, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, et al. Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer’s disease. Int J Geriatr Psychiatry. 2017;32(12):e107–15. https://doi.org/10.1002/gps.4667. This retrospective cohort study included 50,491 patients with AD (Alzheimer’s disease) and 100,982 patients without AD and examined antidepressant use and the risk of hip fractures among older population. Primary outcome was hospitalization due to hip fracture.

    Article  PubMed  Google Scholar 

  54. • Wang SM, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101–12. https://doi.org/10.4068/cmj.2018.54.2.101. This article further examines the side effects of one of the most common medications for an older population. It serves to remind rehabilitation clinicians of the value non-medication approaches to depression .

    Article  PubMed  PubMed Central  Google Scholar 

  55. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomized placebo-controlled trial. Lancet Neurol. 2011;10(2):123–30. https://doi.org/10.1016/S1474-4422(10)70314-8.

    Article  CAS  PubMed  Google Scholar 

  56. Vinik A, Emir B, Parsons B, Cheung R. Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia. Pain Med. 2014;15(4):661–70. https://doi.org/10.1111/pme.12310.

    Article  PubMed  Google Scholar 

  57. • Marcum ZA, Perera S, Thorpe JM, Switzer GE, Castle NG, Strotmeyer ES, et al. Antidepressant use and recurrent falls in community-dwelling older adults: findings from the health ABC Study. Ann Pharmacother. 2016;50(7):525–33. https://doi.org/10.1177/1060028016644466. This study included 2948 older adults (mean age 73.6 years) at baseline (year 1 from the Health, Aging and Body Composition study) and followed through year 7 (1997–2004) with self-reported antidepressant medication use documented at years 1, 2, 3, 5, 6 and further grouped as (1) SSRIs, (2) TCAs, and (3) others, to examine the association between antidepressant use and recurrent falls. The primary outcome was recurrent falls (≥ 2) in the 12 months following self-reported antidepressant medication use.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. • Hanlon JT, Boudreau RM, Roumani YF, Newman AB, Ruby CM, Wright RM, et al. Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci. 2009;64(4):492–8. https://doi.org/10.1093/gerona/gln043. Dr. Hanlon is a prominent researcher and writer in the area of medications and an aging population. This article examines the key factors regarding the number and dosage of CNS active medications in community elders with frequent falls. Preventing or at least reducing falls is a major concern of rehabilitation professionals treating an aging population.

    Article  PubMed  Google Scholar 

  59. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551. https://doi.org/10.1136/bmj.d4551.

    Article  PubMed  PubMed Central  Google Scholar 

  60. • Lien YH. Antidepressants and hyponatremia. Am J Med. 2018;131(1):7–8. https://doi.org/10.1016/j.amjmed.2017.09.002. This commentary in The American Journal of Medicine reviews different studies pertaining to antidepressants and hyponatremia. The author mentions Farmand et al which was another author of a population-based study on second-generation antidepressants and their relevance in hyponatremia. Overall, hyponatremia risk is much higher within 2–4 weeks of starting antidepressants, and the risk seems to diminish over time. By 3–6 months, the hyponatremia risk is the same as for patients who do not take antidepressants. As for each class of antidepressant, the risk of hyponatremia seems to be lower with TCAs and NaSSAs when compared with SSRI and serotonin–norepinephrine reuptake inhibitors.

    Article  PubMed  Google Scholar 

  61. Timonen M, Liukkonen T. Management of depression in adults. BMJ. 2008;336(7641):435–9. https://doi.org/10.1136/bmj.39478.609097.BE.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Morley JE. Orexigenic and anabolic agents. Clin Geriatr Med. 2002;18:853–66.

    Article  Google Scholar 

  63. Fox CB, Treadway AK, Blaszczyk AT, Sleeper RB. Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly. Pharmacotherapy. 2009;29:383–97. https://doi.org/10.1592/phco.29.4.383.

    Article  CAS  PubMed  Google Scholar 

  64. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;12:CD006528. https://doi.org/10.1002/14651858.CD006528.pub2.

    Article  Google Scholar 

  65. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manag. 1995;10(2):89–97.

    Article  CAS  Google Scholar 

  66. Yeh SS, Lovitt S, Schuster MW. Pharmacological treatment of geriatric cachexia: evidence and safety in perspective. J Am Med Dir Assoc. 2007;8(6):363–77. https://doi.org/10.1016/j.jamda.2007.05.001.

    Article  PubMed  Google Scholar 

  67. Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ, Donnelly M. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev. 2012;4:CD008664. https://doi.org/10.1002/14651858.CD008664.pub2.

    Article  Google Scholar 

  68. Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options – a mini-review. Gerantology. 2014;60(4):294–305. https://doi.org/10.1159/000356760.

    Article  CAS  Google Scholar 

  69. Yeh SS, DeGuzman B, Kramer T, M012 Study Group. Reversal of COPD-associated weight loss using the anabolic steroid oxandrolone. Chest. 2002;122(2):421–8. https://doi.org/10.1378/chest.122.2.421.

    Article  CAS  PubMed  Google Scholar 

  70. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90. https://doi.org/10.1001/archinternmed.2010.89.

    Article  PubMed  Google Scholar 

  71. • Safety of long-term PPI use. JAMA. 2017;318(12):1177–8. https://doi.org/10.1001/jama.2017.13272. This is a JAMA medical letter on drugs and therapeutics. It listed all current literature/statements on side effects of long-term PPI use.

  72. Yang YX, Lewis J, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53. https://doi.org/10.1001/jama.296.24.2947.

    Article  CAS  PubMed  Google Scholar 

  73. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–12. https://doi.org/10.1056/NEJMsa1103053.

    Article  CAS  PubMed  Google Scholar 

  74. ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, et al. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i–33i. https://doi.org/10.1016/j.amjcard.2007.03.003.

    Article  Google Scholar 

  75. Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med. 2014;174(2):259–68. https://doi.org/10.1001/jamainternmed.2013.12963.

    Article  CAS  PubMed  Google Scholar 

  76. Chew E, Zafonte RD. Pharmacological management of neurobehavioral disorders following traumatic brain injury-a state-of-the-art review. J Rehabil Res Dev. 2009;46:851–79. https://doi.org/10.1682/JRRD.2008.09.0120.

    Article  PubMed  Google Scholar 

  77. Sawyer E, Mauro LS, Ohlinger MJ. Amantadine enhancement of arousal and cognition after traumatic brain injury. Ann Pharmacother. 2008;42(2):247–52. https://doi.org/10.1345/aph.1K284.

    Article  CAS  PubMed  Google Scholar 

  78. Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366:819–26. https://doi.org/10.1056/NEJMoa1102609.

    Article  CAS  PubMed  Google Scholar 

  79. •• Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, et al. Practice guideline update recommendations summary: disorders of consciousness: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. Neurology. 2018;91(10):450–60. https://doi.org/10.1212/WNL.0000000000005926. This current and expert consensus statement from professional societies in neurology and rehabilitation medicine, and a major federal agency in rehabilitation provides a balanced and informed statement on the management of disorders of consciousness.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Willmott C, Ponsford J, Oliver J, Ponsford M. Safety of methylphenidate following traumatic brain injury: impact on vital signs and side-effects during inpatient rehabilitation. J Rehabil Med. 2009;41(7):585–7. https://doi.org/10.2340/16501977-0369.

    Article  PubMed  Google Scholar 

  81. Alban JP, Hopson MM, Ly V, Whyte J. Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. Am J Phys Med Rehabil. 2004;83(2):131–7. https://doi.org/10.1097/01.phm.0000112308.68586.1d.

    Article  PubMed  Google Scholar 

  82. Kim C, Kwon BS, Nam KY, Park JW, Lee HJ. Zolpidem-induced arousal by paradoxical GABAergic stimulation: a case report with F-18 flumazenil positron emission tomography and single photon emission computed tomography study. Ann Rehabil Med. 2016;40(1):177–81. https://doi.org/10.5535/arm.2016.40.1.177.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Bomalaski MN, Claflin ES, Townsend W, Peterson MD. Zolpidem for the treatment of neurologic disorders: a systematic review. JAMA Neurol. 2017;74(9):1130–9. https://doi.org/10.1001/jamaneurol.2017.1133.

    Article  PubMed  Google Scholar 

  84. Sutton JA, Clauss RP. A review of the evidence of zolpidem efficacy in neurological disability after brain damage due to stroke, trauma and hypoxia: a justification of further clinical trials. Brain Inj. 2017;31:1019–27. https://doi.org/10.1080/02699052.2017.1300836.

    Article  CAS  PubMed  Google Scholar 

  85. •• Mehta S, McIntyre A, Janzen S, Iruthayarajah J, Bateman A, Teasell R. Pharmacological management of agitation among individuals with moderate to severe acquired brain injury: A systematic review. Brain Inj. 2018;32(3):287–96. https://doi.org/10.1080/02699052.2017.1419377. This systematic review addresses the current state of knowledge in one of the most common challenges in PM&R, namely the management of moderate to severe acquired brain injury.

    Article  PubMed  Google Scholar 

  86. Kline AE, Hoffman AN, Cheng JP, Zafonte RD, Massucci JL. Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. Neurosci Lett. 2008;448(3):263–7. https://doi.org/10.1016/j.neulet.2008.10.076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Warden V, Hurley AC, Volicer V. Development and psychometric evaluation of the pain assessment in advanced dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9–15. https://doi.org/10.1097/01.JAM.0000043422.31640.F7.

    Article  PubMed  Google Scholar 

  88. Hoffman AN, Cheng JP, Zafonte RD, Kline AE. Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits. Life Sci. 2008;83(17–18):602–7. https://doi.org/10.1016/j.lfs.2008.08.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210. https://doi.org/10.1097/01.JGP.0000200589.01396.6d.

    Article  PubMed  Google Scholar 

  90. Schneider L, Dagerman K, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43. https://doi.org/10.1001/jama.294.15.1934.

    Article  CAS  PubMed  Google Scholar 

  91. Fuchs-Lacelle S, Hadjistavropoulos T. Development and preliminary validation of the pain assessment checklist for seniors with limited ability to communicate (PACSLAC). Pain Manag Nurs. 2004;5(1):37–49.

    Article  Google Scholar 

  92. Enguidanos S, Herr K, Reid MC, Williams BR. From policy to practice: an interdisciplinary look at labeling changes to OTC analgesics and the implications for patient care. The Gerontological Society of America. 2018.

  93. Qaseem A, Wilt TJ, McLean RM, Forciea MA, Denberg TD, Barry MJ, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514–30. https://doi.org/10.7326/M16-2367.

    Article  PubMed  Google Scholar 

  94. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22(3):363–88. https://doi.org/10.1016/j.joca.2014.01.003.

    Article  CAS  PubMed  Google Scholar 

  95. National Clinical Guideline Centre (UK). Osteoarthritis: Care and Management in Adults. London: National Institute for Health and Care Excellence (UK); 2014 Feb. (NICE Clinical Guidelines, No. 177.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK248069.

  96. FDA Drug Safety Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. From: https://www.fda.gov/Drugs/DrugSafety/ucm239821.htm. Accessed:11/7/18.

  97. Franceschi M, Scarcelli C, Niro V, Seipa D, Pazinza AM, Pepe G, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf. 2008;31(6):545–56. https://doi.org/10.2165/00002018-200831060-00009.

    Article  PubMed  Google Scholar 

  98. • Bally M, Dendukrui N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909. https://doi.org/10.1136/bmj.j1909. This is a systematic review of studies from Canadian and European healthcare databases. A cohort of 446763 individuals including 61460 with acute myocardial infarction was acquired. Taking any dose of NSAIDs for one week, one month, or more than a month was associated with an increased risk of myocardial infarction. Greater risk of myocardial infarction was documented for higher doses of NSAIDs.

    Article  PubMed  PubMed Central  Google Scholar 

  99. U.S. Food and Drug Administration Science Paper: concomitant use of ibuprofen and aspirin: potential for attenuation of the anti-platelet effect of aspirin, 2006. Available at https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm161 282.pdf 19.

  100. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–18. https://doi.org/10.1056/NEJMoa1805819.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379(16):1499–508. https://doi.org/10.1056/NEJMoa1800722.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Catella-Lawson F, Reilly M, Kapoor S, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–17. https://doi.org/10.1056/NEJMoa003199.

    Article  CAS  PubMed  Google Scholar 

  103. Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Luscher TF, et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157(4):606–12. https://doi.org/10.1016/j.ahj.2008.12.014.

    Article  CAS  PubMed  Google Scholar 

  104. Raskin P, Donofrio PD, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J, et al. Topiramate vs. placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology. 2004;63(5):865–73. https://doi.org/10.1212/01.WNL.0000137341.89781.14.

    Article  CAS  PubMed  Google Scholar 

  105. Boyd AL, Barlow PM, Pittenger GL, Simmons KF, Vinik AI. Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2010;3:431–7. https://doi.org/10.2147/DMSOTT.S13699.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. • Wayne AR, Chung CP, Murray KT, Hall K, Stein CM. Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA. 2016;315(22):2415–23. https://doi.org/10.1001/jama.2016.7789. Retrospective cohort study between 1999 and 2012 of Tennessee Medicaid patients with chronic noncancer pain and no evidence of palliative or end-of-life care. Total and cause-specific mortality as determined from death certificates. Adjusted hazard ratios and risk differences were calculated for long-acting opioid therapy vs control medication. 22912 new episodes of prescribed therapy of both long-acting opioids and control medications were noted. Prescription of long-acting opioids for chronic noncancer pain, compared with anticonvulsants or cyclic antidepressants, was associated with a significantly increased risk of all-cause mortality (1.64 HR, Risk difference of 68.5 excess deaths per10,000 person years).

    Article  CAS  Google Scholar 

  107. • Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. JAMA. 2018;319(9):872–82. https://doi.org/10.1001/jama.2018.0899. In this randomized clinical trial that included 240 patients, the use of opioid vs nonopioid medication therapy did not result in significantly better pain-related function over 12 months (3.4 vs 3.3 points on an 11 point scale at 12 months, respectively). Patients were recruited from VA primary care clinics from 6/2013 through 12/2015. 265 patients enrolled, but 25 withdrew prior to randomization and 240 were randomized. In the opioid group, the first step was immediate-release morphine, oxycodone, or hydrocodone/acetaminophen. For the nonopioid group, the first step was acetaminophen or NSAIDs. This study does not support initiation of opioid therapy for moderate to severe chronic back pain or hip or knee osteoarthritis pain.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. • Birke H, Ekholm O, Sjogren P, Kurita GP, Hoisted J. Long-term opioid therapy in Denmark: A disappointing journey. Eur J Pain. 2017;21(9):1516–27. https://doi.org/10.1002/ejp.1053. Longitudinal population-based studies of long-term opioid therapy in chronic non-cancer pain patients. Data were obtained from the national representative Danish Health and Morbidity Surveys and The Danish National Prescription Registry. The selected patients did not have any opioid prescriptions prior to 2000 (n=12,145). 2015 patients completed self-administered questionnaire in both 2000 and 2013. Collected information included chronic pain (>6months), health behavior, self-rated health, pain interference with work activities and physical activities. Results showed long-term opioid therapy did not provide pain relief, quality of life or functional capacity.

    Article  CAS  PubMed  Google Scholar 

  109. Wang Y, Gupta M, Poonawala T, Farooqui M, Li Y, Peng F, et al. Opioids and opioid receptors orchestrate wound repair. Transl Res. 2017;185:13–23. https://doi.org/10.1016/j.trsl.2017.05.003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Gudin JA, Laitman A, Nalamachu S. Opioid related endocrinopathy. Pain Med. 2015;16(S1: Suppl 1):S9–15. https://doi.org/10.11111/pme.12926.

    Article  PubMed  Google Scholar 

  111. Wollman SC, Alhassoon OM, Hall MG, Stern MJ, Connors EJ, Kimmel CL, et al. Gray matter abnormalities in opioid-dependent patients: a neuroimaging meta-analysis. AM J Drug Alcohol Abuse. 2017;43(5):505–17. https://doi.org/10.1080/00952990.2016.1245312.

    Article  PubMed  Google Scholar 

  112. Fournier JP, Azoulay L, Yin H, Montastruc JL, Suissa S. Tramadol use and the risk of hospitalization for hypoglycemic in patients with noncancer pain. JAMA Intern Med. 2015;175(2):186–93.

    Article  Google Scholar 

  113. Lee S, Kim Y, Lee JJS, Im G, Cho JY, Chung JY, et al. A pharmacokinetic drug-drug interaction study between pregabalin and tramadol in healthy volunteers. Eur J Clin Pharmacol. 2018;74:1–9. https://doi.org/10.1007/s00228-018-2543-0.

    Article  CAS  Google Scholar 

  114. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698. https://doi.org/10.1136/bmj.h2698.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. PLoS Med. 2017;14(10):e1002396. https://doi.org/10.1371/journal.pmed.1002396.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomized, 52-week, open-label, safety study. BMC Neurol. 2016;16(1):251. https://doi.org/10.1186/s12883-016-0752-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2012;12(9):CD007400. https://doi.org/10.1002/14651858.CD007400.pub2.

    Article  Google Scholar 

  118. Minhout GS, Alkhalaf A, Kleefstra N, Bilo HJG. Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? Neth J Med. 2010;68(4):158–62.

    Google Scholar 

  119. Benzon HT, Raja SN, Fishman SM, Liu SS, Cohen SP. In: Hurley R, Malik K, Peng P, editors. Essentials of pain medicine: cannabinoids: Elsevier; 2018.

  120. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328–35.

    Article  Google Scholar 

  121. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218. https://doi.org/10.1208/s12248-012-9432-8.

    Article  CAS  PubMed  Google Scholar 

  122. Calder PC. Mechanism of action of (n-3) fatty acids. J Nutr. 2012;142(3):592S–9S. https://doi.org/10.3945/jn.111.155259.

    Article  CAS  PubMed  Google Scholar 

  123. Sandford FM, Sanders TA, Wilson H, Lewis JS. A randomized controlled trial of long-chain omega-3 polyunsaturated fatty acids in the management of rotator cuff related shoulder pain. BMJ Open Sport Exerc Med. 2018;19(4):1:e000414. https://doi.org/10.1136/bmjsem-2018-000414.eCollection.

    Article  Google Scholar 

  124. Suzuki K, Miyamoto M, Hirata K. Sleep disorders in the elderly: diagnosis and management. J Gen Fam Med. 2017;18(2):61–71. https://doi.org/10.1002/jgf2.27.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Wilt TJ, MacDonald R, Brasure M, Olson CM, Carlyle M, Fuchs E, et al. Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med. 2016;165(2):103–12. https://doi.org/10.7326/M15-1781.

    Article  PubMed  Google Scholar 

  126. Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev. 2018;70(2):197–245. https://doi.org/10.1124/pr.117.014381.

    Article  CAS  PubMed  Google Scholar 

  127. • Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136–42. https://doi.org/10.1001/jamapsychiatry.2014.1763. This retrospective descriptive analysis reports that despite cautions concerning risks associated with long-term benzodiazepine use, long-term BZD use remains common in elderly groups. Olfson et al.examined BZD prescriptions during 2008 by sex and age group (18–35 years, 36–50 years, 51–64 years, and 65–80 years). They gave corresponding percentages on the individuals with long-term (>120 days) BZD use, prescription of a long-acting BZD, and BZD prescriptions from a psychiatrist.

    Article  PubMed  Google Scholar 

  128. • Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing. 2011;40(1):23–9. https://doi.org/10.1093/ageing/afq140 Delirium in hospitals and in inpatient rehabilitation settings is quite common and associated with poor outcomes. This article provides a useful review and guidelines to which medications to avoid for people at risk for delirium.

    Article  PubMed  Google Scholar 

  129. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int. 2011;108(41):687–93. https://doi.org/10.3238/arztebl.2011.0687.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rehabilitation Medicine, Emory University School of Medicine, Atlanta, 1441 Clifton Road, Atlanta, GA, 30322, USA

    Sook Kyung Yoon, Britta Adwoa Okyere & Dale Strasser

Authors
  1. Sook Kyung Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Britta Adwoa Okyere
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dale Strasser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dale Strasser.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Geriatric Rehabilitation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoon, S.K., Okyere, B.A. & Strasser, D. Polypharmacy and Rational Prescribing: Changing the Culture of Medicine One Patient at a Time. Curr Phys Med Rehabil Rep 7, 141–158 (2019). https://doi.org/10.1007/s40141-019-00220-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40141-019-00220-z

Keywords

Search

Navigation